Shots:

• The first patient has been dosed in the P-II trial assessing IBI302 in patients with active subfoveal or parafoveal choroidal neovascularization secondary to nAMD. The primary objective is to evaluate the efficacy and safety of IBI302
• The two P- I studies of IBI302 (single/multiple-dose escalation) showed improvement in visual acuity with a reduction in retinal thickness- leakage- and total area of neovascularization in terms of efficacy
• Additionally- the ongoing P-II study of the therapy will focus on improving visual acuity and retinal thickness and the effect on macular atrophy and fibrosis

  Ref: PRNewswire | Image: Innovent